Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001

Kelly A. Gebo, John A. Fleishman, Richard Conviser, Erin D. Reilly, P. Todd Korthuis, Richard D. Moore, James Hellinger, Philip Keiser, Haya R. Rubin, Lawrence Crane, Fred J. Hellinger, W. Christopher Mathews

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

Background: National data from the mid-1990s demonstrated that many eligible patients did not receive highly active antiretroviral therapy (HAART) and that racial and gender disparities existed in HAART receipt. We examined whether demographic disparities in the use of HAART persist in 2001 and if outpatient care is associated with HAART utilization. Methods: Demographic, clinical, and pharmacy utilization data were collected from 10 US HIV primary care sites in the HIV Research Network (HIVRN). Using multivariate logistic regression, we examined demographic and clinical differences associated with receipt of HAART and the association of outpatient utilization with HAART. Results: In our cohort in 2001, 84% of patients received HAART and 66% had 4 or more outpatient visits during calendar year (CY) 2001. Of those with 2 or more CD4 counts below 350 cells/mm3 in 2001, 91% received HAART; 82% of those with 1 CD4 test result below 350 cells/mm3 received HAART; and 77% of those with no CD4 counts below 350 cells/mm3 received HAART. Adjusting for care site in multivariate analyses, age >40 years (adjusted odds ratio [AOR] = 1.13), male gender (AOR = 1.23), Medicaid coverage (AOR = 1.16), Medicare coverage (AOR = 1.73), having 1 or more CD4 counts less than 350 cells/mm3 (AOR = 1.33), and having 4 or more outpatient visits in a year (OR = 1.34) were significantly associated with an increased likelihood of HAART. African Americans (odds ratio [OR] = 0.84) and those with an injection drug use risk factor (OR = 0.86) were less likely to receive HAART. Conclusions: Although the overall prevalence of HAART has increased since the mid-1990s, demographic disparities in HAART receipt persist. Our results support attempts to increase access to care and frequency of outpatient visits for underutilizing groups as well as increased efforts to reduce persistent disparities in women, African Americans, and injection drug users (IDUs).

Original languageEnglish (US)
Pages (from-to)96-103
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume38
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
HIV
Odds Ratio
CD4 Lymphocyte Count
Demography
Outpatients
Ambulatory Care
African Americans
Injections
Medicaid
Medicare
Drug Users
Primary Health Care
Multivariate Analysis

Keywords

  • African American
  • Disparities
  • Female
  • Gender
  • Highly active antiretroviral therapy
  • Injection drug use
  • Race

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. / Gebo, Kelly A.; Fleishman, John A.; Conviser, Richard; Reilly, Erin D.; Korthuis, P. Todd; Moore, Richard D.; Hellinger, James; Keiser, Philip; Rubin, Haya R.; Crane, Lawrence; Hellinger, Fred J.; Mathews, W. Christopher.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 38, No. 1, 01.01.2005, p. 96-103.

Research output: Contribution to journalArticle

Gebo, KA, Fleishman, JA, Conviser, R, Reilly, ED, Korthuis, PT, Moore, RD, Hellinger, J, Keiser, P, Rubin, HR, Crane, L, Hellinger, FJ & Mathews, WC 2005, 'Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001', Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 1, pp. 96-103. https://doi.org/10.1097/00126334-200501010-00017
Gebo, Kelly A. ; Fleishman, John A. ; Conviser, Richard ; Reilly, Erin D. ; Korthuis, P. Todd ; Moore, Richard D. ; Hellinger, James ; Keiser, Philip ; Rubin, Haya R. ; Crane, Lawrence ; Hellinger, Fred J. ; Mathews, W. Christopher. / Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. In: Journal of Acquired Immune Deficiency Syndromes. 2005 ; Vol. 38, No. 1. pp. 96-103.
@article{e9fdf969cb7440b8a7bf5ca82750d630,
title = "Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001",
abstract = "Background: National data from the mid-1990s demonstrated that many eligible patients did not receive highly active antiretroviral therapy (HAART) and that racial and gender disparities existed in HAART receipt. We examined whether demographic disparities in the use of HAART persist in 2001 and if outpatient care is associated with HAART utilization. Methods: Demographic, clinical, and pharmacy utilization data were collected from 10 US HIV primary care sites in the HIV Research Network (HIVRN). Using multivariate logistic regression, we examined demographic and clinical differences associated with receipt of HAART and the association of outpatient utilization with HAART. Results: In our cohort in 2001, 84{\%} of patients received HAART and 66{\%} had 4 or more outpatient visits during calendar year (CY) 2001. Of those with 2 or more CD4 counts below 350 cells/mm3 in 2001, 91{\%} received HAART; 82{\%} of those with 1 CD4 test result below 350 cells/mm3 received HAART; and 77{\%} of those with no CD4 counts below 350 cells/mm3 received HAART. Adjusting for care site in multivariate analyses, age >40 years (adjusted odds ratio [AOR] = 1.13), male gender (AOR = 1.23), Medicaid coverage (AOR = 1.16), Medicare coverage (AOR = 1.73), having 1 or more CD4 counts less than 350 cells/mm3 (AOR = 1.33), and having 4 or more outpatient visits in a year (OR = 1.34) were significantly associated with an increased likelihood of HAART. African Americans (odds ratio [OR] = 0.84) and those with an injection drug use risk factor (OR = 0.86) were less likely to receive HAART. Conclusions: Although the overall prevalence of HAART has increased since the mid-1990s, demographic disparities in HAART receipt persist. Our results support attempts to increase access to care and frequency of outpatient visits for underutilizing groups as well as increased efforts to reduce persistent disparities in women, African Americans, and injection drug users (IDUs).",
keywords = "African American, Disparities, Female, Gender, Highly active antiretroviral therapy, Injection drug use, Race",
author = "Gebo, {Kelly A.} and Fleishman, {John A.} and Richard Conviser and Reilly, {Erin D.} and Korthuis, {P. Todd} and Moore, {Richard D.} and James Hellinger and Philip Keiser and Rubin, {Haya R.} and Lawrence Crane and Hellinger, {Fred J.} and Mathews, {W. Christopher}",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/00126334-200501010-00017",
language = "English (US)",
volume = "38",
pages = "96--103",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001

AU - Gebo, Kelly A.

AU - Fleishman, John A.

AU - Conviser, Richard

AU - Reilly, Erin D.

AU - Korthuis, P. Todd

AU - Moore, Richard D.

AU - Hellinger, James

AU - Keiser, Philip

AU - Rubin, Haya R.

AU - Crane, Lawrence

AU - Hellinger, Fred J.

AU - Mathews, W. Christopher

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: National data from the mid-1990s demonstrated that many eligible patients did not receive highly active antiretroviral therapy (HAART) and that racial and gender disparities existed in HAART receipt. We examined whether demographic disparities in the use of HAART persist in 2001 and if outpatient care is associated with HAART utilization. Methods: Demographic, clinical, and pharmacy utilization data were collected from 10 US HIV primary care sites in the HIV Research Network (HIVRN). Using multivariate logistic regression, we examined demographic and clinical differences associated with receipt of HAART and the association of outpatient utilization with HAART. Results: In our cohort in 2001, 84% of patients received HAART and 66% had 4 or more outpatient visits during calendar year (CY) 2001. Of those with 2 or more CD4 counts below 350 cells/mm3 in 2001, 91% received HAART; 82% of those with 1 CD4 test result below 350 cells/mm3 received HAART; and 77% of those with no CD4 counts below 350 cells/mm3 received HAART. Adjusting for care site in multivariate analyses, age >40 years (adjusted odds ratio [AOR] = 1.13), male gender (AOR = 1.23), Medicaid coverage (AOR = 1.16), Medicare coverage (AOR = 1.73), having 1 or more CD4 counts less than 350 cells/mm3 (AOR = 1.33), and having 4 or more outpatient visits in a year (OR = 1.34) were significantly associated with an increased likelihood of HAART. African Americans (odds ratio [OR] = 0.84) and those with an injection drug use risk factor (OR = 0.86) were less likely to receive HAART. Conclusions: Although the overall prevalence of HAART has increased since the mid-1990s, demographic disparities in HAART receipt persist. Our results support attempts to increase access to care and frequency of outpatient visits for underutilizing groups as well as increased efforts to reduce persistent disparities in women, African Americans, and injection drug users (IDUs).

AB - Background: National data from the mid-1990s demonstrated that many eligible patients did not receive highly active antiretroviral therapy (HAART) and that racial and gender disparities existed in HAART receipt. We examined whether demographic disparities in the use of HAART persist in 2001 and if outpatient care is associated with HAART utilization. Methods: Demographic, clinical, and pharmacy utilization data were collected from 10 US HIV primary care sites in the HIV Research Network (HIVRN). Using multivariate logistic regression, we examined demographic and clinical differences associated with receipt of HAART and the association of outpatient utilization with HAART. Results: In our cohort in 2001, 84% of patients received HAART and 66% had 4 or more outpatient visits during calendar year (CY) 2001. Of those with 2 or more CD4 counts below 350 cells/mm3 in 2001, 91% received HAART; 82% of those with 1 CD4 test result below 350 cells/mm3 received HAART; and 77% of those with no CD4 counts below 350 cells/mm3 received HAART. Adjusting for care site in multivariate analyses, age >40 years (adjusted odds ratio [AOR] = 1.13), male gender (AOR = 1.23), Medicaid coverage (AOR = 1.16), Medicare coverage (AOR = 1.73), having 1 or more CD4 counts less than 350 cells/mm3 (AOR = 1.33), and having 4 or more outpatient visits in a year (OR = 1.34) were significantly associated with an increased likelihood of HAART. African Americans (odds ratio [OR] = 0.84) and those with an injection drug use risk factor (OR = 0.86) were less likely to receive HAART. Conclusions: Although the overall prevalence of HAART has increased since the mid-1990s, demographic disparities in HAART receipt persist. Our results support attempts to increase access to care and frequency of outpatient visits for underutilizing groups as well as increased efforts to reduce persistent disparities in women, African Americans, and injection drug users (IDUs).

KW - African American

KW - Disparities

KW - Female

KW - Gender

KW - Highly active antiretroviral therapy

KW - Injection drug use

KW - Race

UR - http://www.scopus.com/inward/record.url?scp=19944428999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428999&partnerID=8YFLogxK

U2 - 10.1097/00126334-200501010-00017

DO - 10.1097/00126334-200501010-00017

M3 - Article

VL - 38

SP - 96

EP - 103

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -